Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema

Am J Ophthalmol. 2004 Jul;138(1):158-60. doi: 10.1016/j.ajo.2004.02.025.

Abstract

Purpose: To evaluate the duration of the effect of intravitreal triamcinolone acetonide on visual acuity in patients with diffuse diabetic macular edema.

Design: Clinical interventional case series.

Methods: Subjects were 31 patients (38 eyes) with diffuse diabetic macular edema who received an intravitreal injection of 20- to 25-mg triamcinolone acetonide. Mean follow-up time was 13.2 +/- 6.0 months (6.03-25.2 months).

Results: Visual acuity and intraocular pressure began to increase significantly (P =.003) within the first week, reaching a plateaulike maximum at 1 to 7 months postinjection, returning to baseline values 8 to 9 months postinjection.

Conclusions: The effect of an intravitreal injection of approximately 20- to 25-mg triamcinolone acetonide in patients with diffuse diabetic macular edema lasts approximately 7 to 8 months. This information may be helpful in determining the optimal dosage of intravitreal triamcinolone acetonide for the treatment of diffuse diabetic macular edema.

MeSH terms

  • Aged
  • Diabetic Retinopathy / drug therapy*
  • Fluorescein Angiography
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / therapeutic use
  • Humans
  • Injections
  • Intraocular Pressure / drug effects
  • Macular Edema / drug therapy*
  • Time Factors
  • Tomography, Optical Coherence
  • Triamcinolone Acetonide / administration & dosage*
  • Triamcinolone Acetonide / therapeutic use
  • Visual Acuity / drug effects
  • Vitreous Body

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide